# US 2021/0198672 A1 · Aptamer for sclerostin and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198672 A1
- Document ID: US20210198672A1
- Status: Published application
- Kind: A1
- Application number: 16/969,314
- Filed: 2019-02-11
- Published: 2021-07-01
- Earliest claimed: 2018-02-12
- Assignees: Aptacure Therapeutics Limited
- Applicants: Aptacure Therapeutics Limited
- Inventors: Ge Zhang; Yuanyuan Yu; Shuaijian Ni; Yixin He
- Web page: https://patentgrep.com/patent/US20210198672A1

## CPC

- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C12N 2310/16: Aptamers
- C12N 2310/315: Phosphorothioates
- C12N 2310/322: 2'-R Modification
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the field of biomedicine. Specifically, the present invention relates to aptamers against sclerostin and uses thereof, especially uses in the treatment of sclerostin-related diseases such as osteoporosis.

## Claims

### Claim 1

An aptamer against sclerostin, wherein the aptamer
i) comprises a nucleotide sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94% or at least about 95% identity with any one of SEQ ID NOs: 1-17, or
ii) comprises at least 30, at least 35, at least 40, at least 45, at least 50 or more contiguous nucleotides within any one of SEQ ID NOs: 1-17,
preferably, the aptamer comprises a sequence of any one of SEQ ID NOs: 1-17 or 19-24,
wherein the aptamer specifically binds to sclerostin.

### Claim 2 (depends on 1)

The aptamer of claim 1, wherein the aptamer has a Kd to sclerostin of less than 100 nM, preferably less than 50 nM, preferably less than 40 nM, preferably less than 30 nM, preferably less than 20 nM, preferably less than 10 nM or less.

### Claim 3 (depends on 1)

The aptamer of claim 1, wherein the aptamer is capable of inhibiting the biological activity of sclerostin.

### Claim 4 (depends on 1)

The aptamer of claim 1, wherein the aptamer can block the antagonistic effect of sclerostin in a cell-based Wnt signaling assay.

### Claim 5 (depends on 1)

The aptamer of claim 1, wherein the aptamer has an EC50 value of less than 100 μg/ml, preferably less than 50 μg/ml, preferably less than 40 μg/ml, preferably less than 30 μg/ml, preferably less than 20 μg/ml, preferably less than 10 μg/ml or less for inhibiting the biological activity of sclerostin, for example, inhibiting the antagonistic effect of sclerostin on Wnt signaling pathway.

### Claim 6 (depends on 1)

The aptamer of claim 1, wherein the aptamer further comprises one or more modifications that confer enhanced nuclease resistance to the aptamer and/or enhance the in vivo half-life of the aptamer.

### Claim 7 (depends on 6)

The aptamer of claim 6, wherein the modification includes a 3′ inverted deoxythymidine (3′ idT) modification.

### Claim 8 (depends on 6)

The aptamer of claim 6, wherein the modification includes substituting one or more naturally occurring nucleotides with modified nucleotides selected from the group consisting of 2′-fluoro, 2′-methoxyethyl, 2′-methoxy or 2′ allyloxy modified nucleotides, preferably 2′-methoxy modified nucleotides.

### Claim 9 (depends on 6)

The aptamer of claim 6, wherein the modification includes an internucleotide modification, such as an internucleotide phosphorothioate bond modification.

### Claim 10 (depends on 6)

The aptamer of claim 6, wherein the modification includes PEG modification, preferably, the molecular weight of the PEG is about 1 kDa to about 100 kDa, for example, about 40 kDa.

### Claim 11 (depends on 6)

The aptamer of claim 6, wherein the aptamer comprises a 2′-methoxy (2′-OMe) modification, a 3′ inverse deoxythymidine (3′ idT) modification and/or a PEG modification.

### Claim 12 (depends on 1)

A method for treating sclerostin-related diseases, the method comprising administering a therapeutically effective amount of the aptamer against sclerostin of claim 1 to a subject in need thereof, for example, the subject is a human.

### Claim 13 (depends on 12)

The method of claim 12, wherein the sclerostin-related disease is selected from osteoporosis, osteopenia, osteomalacia, osteogenesis imperfecta (OI), ischemic osteonecrosis, rheumatoid arthritis, fracture, osteoarthritis and myeloma.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising at least one aptamer against sclerostin of claim 1, and a pharmaceutically acceptable carrier or excipient.

### Claim 15

(canceled)

### Claim 16

(canceled)
